Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference.

lunes, 12 de enero de 2026, 9:18 am ET1 min de lectura
PCSA--

Processa Pharmaceuticals announced that CEO George Ng and CSO Patrick Lin will attend the 44th Annual J.P. Morgan Healthcare Conference to discuss their clinical pipeline, including the ongoing Phase 2 study of NGC-Cap in advanced breast cancer. Preliminary data show NGC-Cap increases exposure to cancer-killing metabolites while maintaining a comparable safety profile to standard capecitabine monotherapy.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios